3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Os… (NCT04931667) | Clinical Trial Compass
TerminatedPhase 3
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis
Stopped: Study was terminated by Sponsor based on a business decision not due to safety. The study report was finalized without any statistical analysis.
United States72 participantsStarted 2021-07-15
Plain-language summary
This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.
Who can participate
Age range40 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females between 40 and 80 years of age, inclusive, in general good health apart from their knee OA
✓. Femorotibial OA by standard American College of Rheumatology (ACR) criteria; knee OA is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis).
✓. Pain compatible with knee OA for at least 26 weeks prior to the Screening Visit
✓. Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, and benzodiazepine, unless any of these drugs are prescribed by a physician to treat a specific condition
✓. Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
✓. Subjects must have read and understood the informed consent form (ICF), and must have signed and dated it prior to any study-related procedure being performed
Exclusion criteria
✕. Pregnant women, breastfeeding women, and women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) who have a positive or indeterminate pregnancy test result at Screening and Day 1
✕. Women who are not post-menopausal or permanently surgically sterile who are sexually active, and who are not willing to use birth control during the study period
✕. Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Day 1
What they're measuring
1
Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Left Knee
Timeframe: Three Months after Day 1 Injection
2
Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Right Knee
✕. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1
✕. Any condition that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
✕. Any comorbid condition that could affect study endpoint assessments of the knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia
✕. Any contraindications for an IA injection in the knee(s) to be injected at Day 1 in the opinion of the Investigator